C4 Therapeutics Inc (CCCC) — Cash Flow-to-Debt Ratio
C4 Therapeutics Inc (CCCC) has a Cash Flow-to-Debt Ratio of -0.22x as of December 2025, meaning its operating cash flow of $-22.14 Million could theoretically repay 0% of its total liabilities ($102.49 Million) in one year. See CCCC cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
C4 Therapeutics Inc Cash Flow-to-Debt Ratio (2018–2025)
Historical debt coverage capacity for C4 Therapeutics Inc across 8 annual periods. Also explore how fast is C4 Therapeutics Inc growing its equity to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for C4 Therapeutics Inc (2018–2025)
Year-by-year debt coverage analysis for C4 Therapeutics Inc. For market capitalisation and broader financial context, see CCCC market cap overview.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.96x | $-98.69 Million | $102.49 Million | ▼ -97.5% |
| 2024 | -0.49x | $-65.16 Million | $133.62 Million | ▲ +40.5% |
| 2023 | -0.82x | $-106.84 Million | $130.34 Million | ▼ -9.6% |
| 2022 | -0.75x | $-105.94 Million | $141.61 Million | ▼ -0.8% |
| 2021 | -0.74x | $-86.97 Million | $117.16 Million | ▼ -31.7% |
| 2020 | -0.56x | $-67.25 Million | $119.35 Million | ▼ -333.3% |
| 2019 | 0.24x | $55.61 Million | $230.22 Million | ▲ +421.8% |
| 2018 | -0.08x | $-16.98 Million | $226.24 Million | — |